Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2015

View Archived Issues

Galectin Therapeutics finds no drug-drug interaction between GR-MD-02 and midazolam

Merck & Co. funds Canadian research institute collaborations

Mochida and Merck & Co. terminate diabetes collaboration

Epirus licenses Latin American rights to infliximab biosimilar to mAbxience

Lilly and Sanford-Burnham collaborate on immunological therapies

DoD contract provides funding for AcelRx's development of ARX-04

Eisai offers overview of fourth quarter of fiscal 2014

RadioMedix and AREVA Med to codevelop treatment for neuroendocrine tumors

Bristol-Myers Squibb divulges inhibitors of HIV replication

ARHGEF15 shows potential as a prognosic biomarker for PDAC

Serum FGF-21 as a highly sensitive biomarker for early diagnosis of breast cancer

HedgePath receives investment from Mayne Pharma and plans SUBA-Itraconazole trial

Sorrento Therapeutics focuses on immuno-oncology and resiniferatoxin for cancer pain

ADDF grant supports Oryzon's development of ORY-2001 for Alzheimer's disease

Novel approach to identify aggressive susceptibility genes in prostate cancer

Oncolytics Biotech's Reolysin cleared to start pediatric phase I trial in brain tumors

Tacrolimus shows efficacy as the first medical therapy for cherubism

Debiopharm reports results of phase III trial of triptorelin in central precocious puberty

STAT-3 inhibitors: a promising therapy to treat necrotizing enterocolitis

Janssen and Achillion establish global HCV collaboration

French investigators patent chimeric proteins for amyloidosis

Medivir discloses RSV replication inhibitors

Bayer Schering Pharma presents BUB1 inhibitors

Sunshine Lake Pharma develops FFAR1 agonists

Prima BioMed releases final data from phase II ovarian cancer study of CVac

Full results of DELOS trial of idebenone in DMD reported

Invega Trinza approved in U.S. for 3-monthly treatment of schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...